Last updated: 2026-09-09 19:18:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Anavex Life Sciences (AVXL) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2,76, with a market capitalisation of $265,11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2,26 to $10,40. This page covers its latest market performance, valuation, price trends and company information.
$265,11M | |
$2,85 | |
$31,50 | |
$1,25 | |
$2,85 | |
299,46K | |
1,10M | |
-- | |
$10,40 | |
$2,26 | |
-- | |
-- |
Anavex Life Sciences (AVXL) is currently trading at $2,76 as of 2026-09-09 19:17:00, down 3,33% ($0,10) from the previous close of $2,85
During today's regular trading session, AVXL has traded between $1,25 and $31,50, with a trading volume of 299,46K shares. The current price is near the lower end of today's range.
Over the past seven days, Anavex Life Sciences (AVXL) moved from $2,99 to $2,76, representing a decline of 7,86% ($0,24).
The stock traded between $2,75 and $3,13 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 661,40 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6,1%
AVXL is currently trading at $2,76, placing it 6,1% of the way from its 52-week low of $2,26 to its 52-week high of $10,40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 34 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Anavex Life Sciences (AVXL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.